Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
Conditions:   Hormonal Therapy;   Breast CancerIntervention:   Other: Body composition measurementSponsor:   Centre Jean PerrinRecruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2015 Category: Research Source Type: clinical trials

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Degarelix;   Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: EstramustineSponsor:   The University of Texas Health Science Center, HoustonNot yet recruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2015 Category: Research Source Type: clinical trials

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
Conditions:   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast CancerInterventions:   Behavioral: Telephone-Based Intervention;   Other: Survey Administration;   Other: Laboratory Biomarker AnalysisSponsor:   Ohio State University Comprehensive Cancer CenterRecruiting - verified...
Source: ClinicalTrials.gov - March 23, 2015 Category: Research Source Type: clinical trials

Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
Condition:   Breast NeoplasmsInterventions:   Drug: Tamoxifen;   Drug: Vorinostat;   Drug: pembrolizumabSponsor:   Pamela MunsterActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2015 Category: Research Source Type: clinical trials

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy
Condition:   Endocrine Sensitive HER2+/HR+ Breast CancerIntervention:   Drug: PertuzumabSponsors:   Istituto Oncologico Veneto IRCCS;   AS.T.R.O. Association for Translational Research in OncologyRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2015 Category: Research Source Type: clinical trials

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   ER-positive Breast CancerInterventions:   Drug: fulvestrant 500 mg;   Drug: Docetaxel (T) 75 mg/m2 (Taxotere);   Drug: Trastuzumab (H, 8mg/kg;   Drug: Pertuzumab (P, 840 mgSponsor:   Western Regional Medical CenterRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2015 Category: Research Source Type: clinical trials

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
Condition:   Estrogen Receptor Positive Breast CancerIntervention:   Drug: hydroxychloroquineSponsor:   Western Regional Medical CenterRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2015 Category: Research Source Type: clinical trials

Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: everolimus;   Drug: anastrozole;   Drug: letrozole;   Drug: tamoxifen citrate;   Drug: fulvestrant;   Drug: megestrol ...
Source: ClinicalTrials.gov - October 20, 2014 Category: Research Source Type: clinical trials

Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)
Condition:   Prostate CancerIntervention:   Device: AR-v7 assaysSponsors:   Duke University;   Weill Medical College of Cornell University;   Johns Hopkins University;   Dana-Farber Cancer Institute;   Memorial Sloan-Kettering Cancer Center;   Epic Sciences;   Prostate Cancer FoundationNot yet recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2014 Category: Research Source Type: clinical trials

Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: everolimus;   Drug: anastrozole;   Drug: letrozole;   Drug: tamoxifen citrate;   Drug: fulvestrant;   Drug: megestrol ...
Source: ClinicalTrials.gov - October 17, 2014 Category: Research Source Type: clinical trials